zonisamide has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 10 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| " No unexpected neurological or psychiatric adverse events occurred, and no adverse events increased in incidence in the open-label period." | 3.11 | Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial. ( Hasegawa, K; Kajiwara, R; Kosaka, K; Murata, M; Odawara, T; Tagawa, M; Takeuchi, H, 2022) |
| " Other outcomes included the changes in Mini-Mental State Examination (MMSE) and Neuropsychiatric Inventory-10 (NPI-10) scores, and the incidence of adverse events." | 3.01 | Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials. ( Hasegawa, K; Kochi, K; Konishi, O; Maruyama, H; Odawara, T; Toya, S, 2021) |
| " Chronic administration of L-DOPA plus ZNS in PD model mice was shown to increase the duration and severity of LID compared with PD model mice that were treated with L-DOPA alone." | 1.51 | The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice. ( Nambu, A; Sano, H, 2019) |
| " Chronic administration of zonisamide in Engrailed mutant mice was shown to improve the survival of nigrostriatal dopaminergic neurons compared with that under saline treatment." | 1.42 | Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease. ( Murata, M; Nambu, A; Sano, H, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, K | 2 |
| Kochi, K | 1 |
| Maruyama, H | 1 |
| Konishi, O | 1 |
| Toya, S | 1 |
| Odawara, T | 3 |
| Kajiwara, R | 1 |
| Takeuchi, H | 1 |
| Tagawa, M | 1 |
| Kosaka, K | 1 |
| Murata, M | 2 |
| Hinkle, JT | 1 |
| Pontone, GM | 1 |
| Hershey, LA | 1 |
| Irwin, DJ | 1 |
| Sano, H | 2 |
| Nambu, A | 2 |
| Shiozaki, K | 1 |
| Togo, T | 1 |
| Hirayasu, Y | 1 |
| Yokoyama, H | 2 |
| Yano, R | 2 |
| Kuroiwa, H | 2 |
| Tsukada, T | 2 |
| Uchida, H | 2 |
| Kato, H | 2 |
| Kasahara, J | 2 |
| Araki, T | 2 |
| Choudhury, ME | 1 |
| Moritoyo, T | 1 |
| Yabe, H | 1 |
| Nishikawa, N | 1 |
| Nagai, M | 1 |
| Kubo, M | 1 |
| Matsuda, S | 1 |
| Nomoto, M | 1 |
2 trials available for zonisamide and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials.
Topics: Aged; Anticonvulsants; Double-Blind Method; Female; Humans; Japan; Lewy Body Disease; Male; Neuropsy | 2021 |
Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial.
Topics: Double-Blind Method; Humans; Lewy Body Disease; Outpatients; Parkinsonian Disorders; Treatment Outco | 2022 |
8 other studies available for zonisamide and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Invited Perspective on the "Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial".
Topics: Double-Blind Method; Humans; Lewy Body Disease; Parkinsonian Disorders; Zonisamide | 2022 |
Zonisamide for DLB parkinsonism: An old drug used in a new context.
Topics: Double-Blind Method; Humans; Levodopa; Lewy Body Disease; Parkinsonian Disorders; Zonisamide | 2018 |
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
Topics: Animals; Anticonvulsants; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopam | 2019 |
Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Brain; Brain-Derived Neurotrophic Factor; Dopaminergic | 2015 |
Administration of zonisamide in three cases of dementia with Lewy bodies.
Topics: Aged; Antiparkinson Agents; Caregivers; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |
Zonisamide attenuates MPTP neurotoxicity in marmosets.
Topics: Animals; Antiparkinson Agents; Callithrix; Corpus Striatum; Dopamine; Female; Humans; Isoxazoles; Ma | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease M | 2010 |